CD22 and colonic neoplasm: While we are devoid of a specific explanation for the discordance between our results and those previously published by Prokop and colleagues, it is possible to assume that the different cellular background between the two studies (colon cancer cells in the paper by Prokop et al. vs Burkitt's lymphoma and ALL cells in our study) or the use of the unconjugated drug (i.e., free calicheamicin unbound to the anti-CD22 antibody epratuzumab in the Prokop study) may have significantly contributed to these diverging results.